Glaukos Announces Co.'s iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study; 'Reports 24-Month Average IOP Reductions of 7.9 mmHg and 7.4 mmHg in Fast- and Slow-Release iDose TR Arms, Respectively'